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[CONDENSATION] 47 
In sheep and humans there is variability in the maturation of the preterm fetal lung in 48 
response to antenatal steroid treatment. In the present study this variation was not associated 49 
with differences in maternal or fetal steroid plasm concentrations. 50 
 51 
[SHORT TITLE] 52 
Variability in fetal sheep lung responses to antenatal steroids. 53 
 54 
[AJOG at a Glance] 55 
A. Why was this study conducted? 56 
Antenatal steroids (ANS) are a widely used treatmen to improve outcomes for preterm 57 
infants, principally by maturing the fetal lung and stabilizing the cardiovascular system. 58 
Treatment efficacy is highly variable, even when potentially confounding factors (i.e. 59 
treatment to delivery interval, agent, dose) are standardized. Hypothesizing that differences in 60 
materno-fetal steroid exposure contribute to observed variability in ANS treatment efficacy, 61 
we used a chronically catheterized sheep model of pregnancy and post-natal ventilation to 62 
test if the relationship between materno-fetal steroid exposure and functional lung maturation 63 
explained variation in lung maturation effects.   64 
 65 
B. What are the key findings? 66 
Following a main-group analysis to confirm overall effect, preterm lambs which had been 67 
exposed to a single maternal antenatal injection of 0.25 mg/kg betamethasone (as 1:1 68 
betamethasone phosphate and betamethasone acetate) were stratified to either a responder 69 
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group or a non-responder group, based upon arterial PaCO2 levels at 30 minutes ventilation 70 
being within two standard deviations of the mean value for Control Group (Saline only) 71 
fetuses. No differences in betamethasone distribution, clearance, or protein binding ratio were 72 
observed between responder and non-responder ANS treatment groups. 73 
 74 
C. What does this study add to what is already known? 75 
This study correlated individual maternal and fetal ANS drug exposures with treatment 76 
efficacy as determined by functional lung maturation. Our data showed that observed 77 
differences in ANS treatment efficacy between identically-dosed animals were not due to 78 
differences in materno-fetal drug exposure. Differences may be due to fetus or 79 
pregnancy-specific factors that modify individual steroid responses. 80 
 81 
[SELECTED FIGURE] 82 
Figure 5.  83 
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[ABSTRACT] 84 
Background: Antenatal steroids (ANS) are standard of care for w men judged to be at 85 
imminent risk of preterm delivery. Worldwide, there is significant variation in ANS dosing 86 
strategy, selection for treatment criteria, and agent choice. This, combined with very limited 87 
optimization of ANS use per se means that treatment efficacy is highly variable and the rate 88 
of respiratory distress syndrome is decreased perhas as little as 40%. In some cases, ANS 89 
use is associated with limited benefit and potential harm.  90 
Objective: We hypothesized that individual differences in maternal and fetal steroid exposure 91 
would contribute to observed variability in ANS treatment efficacy. Using a chronically 92 
catheterized sheep model of pregnancy, we aimed to explore the relationship between 93 
materno-fetal steroid exposure and ANS treatment efficacy as determined by functional lung 94 
maturation in preterm lambs undergoing ventilation. 95 
Methods: Ewes carrying a single fetus had surgery to catheterize a fetal and maternal jugular 96 
vein at 119 days’ gestation. Animals recovered for 24h before being randomized to 97 
either: i) a single maternal intramuscular injection (IM) of 2ml saline (Negative Control 98 
Group, n=10); or ii) a single maternal IM of 0.25mg/kg betamethasone phos ate + 99 
acetate (ANS Group, n=20). Serial maternal and fetal plasma samples were collected from 100 
each animal over 48h before fetuses were delivered and ventilated for 30 minutes. Total 101 
and free plasma betamethasone concentration was measured by mass spectrometry. Fetal lung 102 
tissue was collected for analysis using quantitative polymerase chain reaction. 103 
Results: One animal of the Control Group and one animal from the ANS Group had did not 104 
complete their treatment protocol and were removed from analyses. Animals in the ANS 105 
Group were divided into a Responder (n=12/19) Sub-Group and a Non-Responder 106 
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Sub-Group (n=7/19) using a cut-off of a PaCO2 at 30 minutes ventilation within 2SD of the 107 
mean value from saline-treated Negative Control Group animals. While ANS improved fetal 108 
lung maturation in the undivided ANS group, and in the Responder Sub-Group both 109 
physiologically (blood gas and ventilation related data) and biochemically (mRNA 110 
expression related to fetal lung maturation), these values were not improved relative to 111 
saline-treated Control Group animals in the ANS Non-Responder Sub-Group. Interestingly, 112 
no differences in betamethasone distribution, clearance, or protein binding were identified 113 
between the ANS Responder and Non-Responder Sub-Groups. 114 
Conclusion: This study correlated individual materno-fetal steroid exposures with preterm 115 
lung maturation as determined by pulmonary ventilation. Herein, approximately 40% of 116 
preterm lambs exposed to antenatal steroids had lung maturation not significantly different to 117 
saline-treated Control Group animals. These non-responsive animals received maternal and 118 
fetal betamethasone exposures identical to animals th t had a significant improvement in 119 
functional lung maturation. These data suggest that the efficacy of ANS therapy is not solely 120 
determined by materno-fetal drug levels, and that indiv dual fetal or maternal factors may 121 
play a role in determining treatment outcomes in response to glucocorticoid-driven signaling. 122 
 123 
[KEYWORDS] 124 
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Preterm birth is a leading cause of neonatal morbidity and mortality. Antenatal steroids 131 
(ANS) are a standard of care for women at risk of delivering preterm. The American College 132 
of Obstetricians and Gynecologists, for example, recommends the use of ‘a single course of 133 
corticosteroids for pregnant women between 24 0/7 weeks and 33 6/7 weeks of gestation who 134 
are at risk of preterm delivery within 7 days’. 1 However despite extensive use, ANS dosing, 135 
choice of agent, and patient selection remains relativ y unchanged and poorly unoptimized 136 
after almost 50 years of clinical use. 2 ANS treatment is considered among the most important 137 
therapies to improve outcomes for preterm babies and has been used widely since Liggins 138 
and Howie reported the beneficial effect of ANS in a cohort of babies born between 28 and 139 
32 weeks’ gestation in their landmark 1972 paper. 3 There is significant geographical 140 
variation in the usage of ANS; highlighting the different doses and agents employed (and 141 
derivative differences in materno-fetal pharmacokinetics and pharmacodynamics), the United 142 
Kingdom and Japan commonly use 12 mg maternal intramuscular injections of 143 
betamethasone phosphate given 24 hours apart. 4 The WHO-recommended dosing regimen is 144 
four 6 mg maternal intramuscular injections of dexamethasone phosphate given 12 hours 145 
apart for pregnant women who are at risk of preterm labor between 24 and 34 weeks of 146 
gestation. 5 In the United States, Australia, and much of Europe, a course of two maternal 147 
intramuscular injections of 12mg 1:1 betamethasone acetate and betamethasone phosphate 148 




A recent Cochrane systemic review reported that a single course of ANS treatment for 152 
singleton pregnancies between 26 and 34 weeks of gestation contributed to a significant 153 
reduction in adverse outcomes including perinatal and neonatal death, respiratory distress 154 
syndrome (RDS) and intraventricular hemorrhage.6 When given to the right women and the 155 
right time, the benefit derived from ANS use are well-documented. However, efficacy is 156 
variable and there is evidence from both clinical and nimal studies to suggest that unwanted 157 
side effects such as growth restriction and programming changes are associated with repeated 158 
ANS exposure. 7, 8 Current clinical dosing (12mg 1:1 betamethasone acetate and phosphate) 159 
achieves betamethasone concentrations in the fetal plasma peak at around 20 ng/ml in 2 hours 160 
after the first administration.9 Using a sheep model of pregnancy, we have previously 161 
demonstrated that high dose ANS treatment is not necessary for lung maturation, and that 162 
maintaining low fetal plasma betamethasone concentration in the range of 1-4 ng/mL for a 163 
period of 26 or 36 hours resulted in fetal lung matur tion equivalent to effects seen with the 164 
current clinical dose when delivery occurred 48h after treatment initiation.10 Additionally, a 165 
24 hour fetal ANS exposure (i.e. single clinical dose of betamethasone) was sufficient for 166 
lung maturation of 24-48 hour post-treatment deliver es.11  167 
 168 
The highly variable efficacy of ANS treatment is well documented clinically. 5, 6 We have 169 
also observed significant variation in our experimental animals, despite them being 170 
gestational age matched, receiving an identical weight-calibrated ANS dose, and being 171 
delivered for ventilation at an identical treatment to delivery interval. We hypothesized that 172 
these observed differences were due to individual differences in the distribution or clearance 173 
of steroids from the materno-fetal compartments. To test this hypothesis we used a 174 
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chronically catheterized sheep model of pregnancy to explore the relationship between 175 
materno-fetal steroid exposure and ANS treatment efficacy as determined by functional lung 176 
maturation in preterm lambs undergoing ventilation. We hypothesized that the levels of total 177 
and free (unbound) betamethasone in fetal plasma would correlate with the extent of the lung 178 





















Animal work 199 
All protocols were reviewed and approved by the animal ethics committee of The University 200 
of Western Australia (RA/3/100/1636). This was a basic science study. Animals were 201 
randomized to treatments, and post-natal ventilations / analyses were performed by 202 
investigators blinded to treatments (i.e. Saline or ANS Group allocation) to defend against 203 
bias or confounding. 204 
 205 
All pregnant ewes were provided from a single supplier and experiments were performed 206 
during the normal breeding season. In order to prevent preterm labor, thirty date-mated ewes 207 
carrying singleton fetus received an intramuscular injection of 150mg medroxyprogesterone 208 
acetate (Depo-Ralovera®; Pfizer, West Ryde, NSW, Australia) at 114±1 days of gestational 209 
age (term = 150 days). This treatment has been previously shown to have no influence on 210 
lung maturation in sheep models.12 Five days later all pregnant ewes underwent recovery 211 
surgery to catheterize the maternal and fetal jugular veins as previously described, with 212 
catheter lines exteriorized through a flank port and secured in a sterile container adherent to 213 
the ewe’s back as previously described.13 Animals recovered for 24 hours before being 214 
randomized to one of two groups: either i) a single maternal intramuscular injection of 2 ml 215 
saline (Control Group, n=10); or ii) a single maternal intramuscular injection of 0.25 mg/kg 216 
betamethasone acetate + betamethasone phosphate (Celeston  Chronodose, Merck Sharp & 217 
Dohme, Australia) (ANS Group, n=20) at 120±1 days of gestational age. We have previously 218 
demonstrated an efficacious response from this dosein the sheep model of pregnancy. 2-3ml 219 
of maternal and fetal blood was collected at 13 time points from jugular catheters over 48 220 
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hours following saline or betamethasone administratons (Collection time points: -10 minutes, 221 
1 , 2, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 hours). Samples were centrifuged at 3000 x g to 222 
separate plasma, which was then frozen at -80°C for subsequent analysis. Half of the plasma 223 
at the 1, 6, 12, 24, 36, 48 hour time points was colle ted into Centrifree® Ultrafiltration 224 
Devices (EMD Millipore Corporation. Billerica, MA, USA) and centrifuged at 1000 x g for 225 
ten minutes at room temperature to separate free from protein-bound betamethasone. A pilot 226 
experiment was performed initially to show that there was no difference in free:bound 227 
betamethasone yield when extractions were performed at room temperature (23°C) or sheep 228 
core temperature (38.9°C) (data not shown). Lambs were delivered under terminal anesthesia 229 
for a 30 minute ventilation procedure at the conclusion of the 48h sampling period to test for 230 
functional lung maturation.13  231 
 232 
Ventilation 233 
At 122±1 days gestational age, pregnant ewes receivd an intravenous injection of 234 
midazolam (0.5 mg/kg) and ketamine (10 mg/kg) followed by a 3mL spinal injection of 235 
lidocaine (20 mg/ml) for surgical delivery. After surgical delivery, the lamb received an 236 
intramuscular injection of ketamine (10 mg/kg) and a 4.5Fr endotracheal tube was placed by 237 
tracheostomy. Lambs were then weighed, dried, and placed on a temperature controlled 238 
radiant warmer (Cosy Cot, Fisher & Paykel Healthcare, New Zealand). Mechanical 239 
ventilation using Acutronic Fabian infant ventilators (Acutronic Medical System, Hirzel, 240 
Switzerland) was started immediately and maintained for 30 minutes on the following 241 
setting: peak inspiratory pressure (PIP) of 35 cmH2O, positive end expiratory pressure 242 
(PEEP) of 5 cmH2O, respiratory rate of 50 breaths per minutes, inspiratory time of 0.5 243 
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seconds, and 100% heated and humidified oxygen. An umbilical artery catheter was placed to 244 
measure arterial blood pH, pO2, pCO2, heart rate and blood pressure during ventilation. 245 
Ventilation efficacy index (VEI) was calculated as follows: VEI = 3800 / [ respiratory rate 246 
(PIP – PEEP) x pCO2 (mmHg)].
14 The investigators that performed ventilations were blind to 247 
treatment allocation. 248 
 249 
Necropsy 250 
Ewes and lambs were euthanized with an intravenous lethal dose of pentobarbital. At 251 
necropsy, the lamb’s chest was opened surgically to measure lung compliance with a static 252 
pressure volume curve. The lungs were then removed and weighed. The right lower lobe was 253 
dissected and frozen for molecular studies. 254 
 255 
Measurement of transcript expression changes in the fetal lung 256 
RNA was extracted from lung tissue (right lower lobe) using RNeasy® Plus Mini Kit 257 
(QIAGEN, Hilden, Germany) in accordance with the manuf cturer’s instructions. The 258 
concentration of extracted ribonuclease acid was determined using a broad-range acid 259 
quantitation kit and a Qubit 2.0 fluorometer (both Life Technologies, Carlsbad, CA). All 260 
ribonuclease acid (RNA) extracts were diluted in nuclease-free water (Life Technologies) to 261 
achieve a final RNA concentration of 25 ng/µL. 262 
 263 
Quantitative polymerase chain reaction (qPCR) cycling was performed with ovine-specific 264 
TAQMAN probe and primer sets (Applied Biosystems, Foster City, CA) with a Step One 265 
Real-Time PCR system in accordance with manufacturer’s instructions. Messenger RNA 266 
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transcripts for surfactant protein A (SP-A), surfactant protein B (SP-B), surfactant protein C 267 
(SP-C), aquaporins 1 (AQP-1), aquaporins 5 (AQP-5) and epithelial sodium channel subunits 268 
B (ENaC-B) were measured. Ribosomal protein 18s wasused as internal reference to 269 
normalize the amplification data for each gene. Delta quantification cycle values were used to 270 
determine relative expression of transcripts. 271 
 272 
Measurement of plasma free and total (free + bound) betamethasone concentration by mass 273 
spectrometry 274 
Unfiltered plasma collected from maternal and fetal blood samples was used to analyze total 275 
(free and bound) betamethasone concentration. Filtered plasma separated by Centrifree® 276 
Ultrafiltration Devices was analyzed to measure free (unbound) betamethasone 277 
concentration.  278 
 279 
Plasma samples and betamethasone standards (200, 100, 40, 20, 10, 2, 1, 0 ng/ml) in control 280 
fetal plasma were extracted as previously described and analyzed by mass spectrometry.13 281 
Quality control samples were run in duplicated across the experiment to determine assay 282 
precision. Intraassay coefficient of variation was 0.8-7.2 %. The interassay coefficient of 283 
variation was 4.8 %. Data were fitted to a 2-compartmetnt model with PKSOLVER.15 All R2 284 
values for calibration curves were >0.99. 285 
 286 
Definition of ANS Responder and Non-Responder Sub-Groups 287 
ANS Group animals (1 x 0.25mg/kg 1:1 betamethasone phosphate + betamethasone acetate) 288 
were initially analysed as a single group to confirm overall treatment benefit before being 289 
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divided into Responder or Non-Responder Sub-Groups n the basis of arterial PaCO2 levels 290 
at 30 minutes ventilation. A value of 2 standard divisions (SD) from the average of arterial 291 
PaCO2 at 30minutes ventilation from Control Group animals was used as an arbitrary, a 292 
priori cut-off for sub-group distribution, based on our ea li r work with this model system. 293 
The Responder Sub-Group was defined as arterial PaCO2 level more extreme than 2SD from 294 
the Control Group mean, and the Non-Responder Sub-Group was defined as an arterial 295 
PaCO2 level within 2SD of the Negative Control Group mean.  296 
 297 
Statistical analysis 298 
Statistical analysis was performed using IBM SPSS for Windows, version 25.0 (IBM Corp, 299 
Armonk, NY). Mean differences between parametric data were tested for significance with 300 
t-test or Mann-Whiney test. The Control Group was fir t compared with the ANS Group as a 301 
primary analysis. Thereafter, comparisons between the Responder Sub-Group and the 302 
Non-Responder Sub-Group were performed. In the Sub-Group analysis, only parameters that 303 
were identified as significantly different in the primary analysis were assessed. Comparisons 304 
of betamethasone concentration were performed by t-test or Mann-Whiney test. Significant 305 
was attributed to 95% confidence interval (95% CI) or P values <.05. 306 
 307 
  308 
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[RESULTS] 309 
One animal in each of the Control and ANS groups failed to complete their treatment 310 
protocol and were removed from further analyses. Nine lambs in the Control Group and 19 311 
lambs in the ANS Group completed their assigned protocols. The ANS Group was divided 312 
into Responder (n=12) and Non-Responder (n=7) Sub-Groups as described above. The 313 
betamethasone treatment efficacy rate was 63% based on the cut-off. There were no 314 
significant differences in gestational age, birth weight, sex, cord blood pH, cord PaCO2, or 315 
lung weight at delivery between primary groups and sub-groups (Table 1).  316 
 317 
30 minute ventilation results 318 
Figure 1 and Supplementary Table 1 present key physiological variables and arterial blood 319 
gas measurements after 30 minutes of ventilation. Given a 30 minute PaCO2 for Control 320 
Group of 129.8±19.4 mmHg, the PaCO2 cut-off for determining ANS response was 91.0 321 
mmHg. Only one animal in the Control Group had a 30 minute PaCO2 lower than the 322 
arbitrary cut-off (89.6 mmHg) used for sub-group analyses. As this animal was not 323 
statistically an outlier it was retained for subsequ nt analyses.  324 
 325 
At primary analysis, there were significant increases in pH and PaO2 in the ANS Group 326 
relative to the Control Group. PaCO2 and heart rate decreased significantly in the ANS Group 327 
compared to the Control Group. There was no significant difference in mean blood pressure 328 
between the Control Group and the ANS Group. For Sub-Group analyses, pH, PaO2, PaCO2 329 
and heart rate were analysed.There were significant ncreases in pH and PaO2 and significant 330 
decreases in PaCO2 and HR after 30 minutes ventilation in the Responder Sub-Group 331 
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compared to the Non-Responder Sub-Group. 332 
 333 
Tidal volume and VEI after 30 minutes ventilation was significantly improved in the ANS 334 
Group relative to the Control Group while there was no difference in dynamic compliance 335 
(Figure 2). Sub-Group analysis showed that both tidal volume and VEI were increased 336 
significantly in the Responder Sub-Group compared with the Non-Responder Sub-Group. 337 
Dynamic compliance was not analyzed in Sub-Group analysis. Animals in the ANS Group 338 
had significantly improved static lung compliance compared with the Control Group at 339 
primary analysis. The Responder Sub-Group showed a significant improvement in static lung 340 
compliance compared with the Non-Responder Sub-Group, as demonstrated by the 341 
pressure-volume curve and lung gas volume at 40 mmH2O (Figure 3). There was no evidence 342 
of gross lung injury in any of the groups.  343 
 344 
Quantitative polymerase chain reaction analysis of transcript expression changes in the fetal 345 
lung 346 
At primary analysis, relative to the Control Group, significant increases were detected in the 347 
relative expression of transcripts for SP-A, SP-C, AQP-1, AQP-5 and ENaC-B in the ANS 348 
Group while there was no significant differences in SP-B between the Control Group and the 349 
ANS Group. At Sub-Group analysis, there was no significant difference in the relative 350 
expression of transcripts between the Responder Sub-Group and Non-Responder Sub-Group. 351 




Total and free betamethasone measurements 355 
Total betamethasone concentration in maternal and fetal plasma was analyzed at 13 serial 356 
time points. Free betamethasone concentration was an lyzed at 6 serial points. Maternal and 357 
fetal exposure to betamethasone was calculated by determining area under the curve. There 358 
were no significant differences in maternal and fetal total or free betamethasone, the 359 
betamethasone half-life, maximum concentration time, aximum concentration and area 360 
under the curve between the Responder Sub-Group and the Non-Responder Sub-Groups 361 
(Figure 5, Supplementary table 2).  362 
  363 
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[COMMENT] 364 
Principal Findings 365 
This study showed that animals in the ANS group (receiving one clinical dose of ANS 366 
treatment - 0.25mg/kg betamethasone phosphate and acetate) had improved lung maturation 367 
physiologically at 48 hours after the treatment relative to animals in Control Group which 368 
were treated with saline. Observed treatment efficacy was variable, with ~40% of preterm 369 
lambs failing to respond to treatment. ANS Group Responder and Non-Responder 370 
Sub-Groups could established based on an PaCO2 levels after 30 minutes of ventilation. 371 
 372 
Among animals in the ANS Group, there was no difference in betamethasone 373 
pharmacokinetics, including protein binding (i.e. free:bound betamethasone in plasma) 374 
between the Responder Sub-Group and the Non-Responder Sub-Group.  These data suggest 375 
that, at least in the sheep model of pregnancy, observed variation in standardized ANS 376 
treatments are likely due to pregnancy or fetus-specific factors impacting how the fetus 377 
responds to an otherwise comparable glucocorticoid exposure. We hypothesized that 378 
variability in ANS treatment efficacy in previously observed in experiments involving the 379 
sheep model of pregnancy could be explained, at leas in part, by differences in individual 380 
clearance and distribution of betamethasone in the maternal and fetal compartments. This 381 
hypothesis was not supported by our study findings.  382 
 383 
The initial primary analysis showed that ANS treatment improved lung maturation as 384 
demonstrated by blood gas analysis and ventilation analysis. Moreover, ANS promoted 385 
alterations in mRNA expression which were consistent with lung maturation. These changes 386 
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were similar to those seen in our previous experiments with this model system. 16  387 
 388 
Sub-Group analysis showed ANS efficacy  in just 60% of treated animals. An arbitrary 389 
cut-off value 2 SD lower than average of PaCO2 at 30minutes ventilation in the control group 390 
was an appropriate means of interrogative ANS respon iveness based on the experimental 391 
design. Other markers, such as PaO2 may not have been such a robust maker of lung 392 
maturation, because of variation in ductus arteriosus in size and flow direction may have 393 
impacted values.17  394 
 395 
After administration, drugs have the potential to bind to serum in the blood. In particular, 396 
betamethasone predominantly binds to serum albumin or alpha-1-acid glycoprotein (AGP). It 397 
is believed that free drugs, not bound to protein, are better able to traverse biological 398 
membranes of cells and exert their pharmacological effects.18, 19.  399 
 400 
We used Centrifree Ultrafiltration Devices with a nominal molecular weight limit of 30 kDa. 401 
Considering albumin and AGP have a molecular weight greater than 30 kDa, we suggest that 402 
this approach provides a robust means of easily separating free betamethasone from bound 403 
betamethasone.20 While physiological and molecular results in the ANS Responder 404 
Sub-Group were significantly different from those of the ANS Non Responder Sub-Group, no 405 
differences (particularly in drug half-life and AUC), were identified between these groups. 406 
Therefore, we concluded that our hypothesis was incorre t, and that the observed variation in 407 
ANS treatment efficacy was not due to betamethasone clearance, plasma protein binding, or 408 
distribution.  409 
 20
Clinical Implications 410 
Although ANS therapy has been widely adopted, the dosing strategy employed has remained 411 
largely unoptimized for some 50 years. Additionally, it is important to recognize that a 412 
significant percentage of human fetuses appear to be similarly non-responsive to ANS 413 
treatment. From a clinical standpoint it is important to consider that, despite effectively 414 
controlling for gestational age, plurality, dose, agent and time to delivery interval, only ~60% 415 
of animals in the ANS Group in this study responded positively to treatment. It is unclear, 416 
given the range of factors involved, if such control can be achieved in a clinical setting, and 417 
this may be reflected in the apparently lower rate of benefit; based on Cochrane Review, ANS 418 
reduced RDS by 40 %.6 A significant percentage of this variation will almost certainly be due 419 
to factors such as agent used and treatment to delivery interval; however it seems reasonable 420 
to suggest, based on evidence of variability in adult responsiveness to steroid treatments, and 421 
data presented herein, that a meaningful percentage v riation of human preterm response to 422 
ANS therapy likely derives from individual differences in steroid responsiveness - rather than 423 
drug exposure per se.21 424 
 425 
This is an important avenue of future investigation given both the potential benefits deriving 426 
from appropriate ANS application, and the risks conveyed by off-target use, with repeated 427 
courses of ANS having received particular attention. 8, 22  In some centers, more than half of 428 
the preterm babies treated with ANS are born outside the proposed ANS treatment efficacy 429 
window (24 hours to 7 days post administration), because predicting the timing of preterm 430 
labor precisely and judging the timing of ANS therapies adequately is often difficult.23, 24  431 
 432 
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Strengths and Limitations 433 
In assessing these data, it is important to reiterate that they were generated in a sheep model 434 
of pregnancy using a small number (relative to a clinical efficacy study) of surgically 435 
manipulated animals. The direct translatability of these data to the human clinical scenario 436 
remains to be established; however, the sheep has to date proven a high-fidelity model for the 437 
development of ANS therapy, and a similar degree of variability in treatment efficacy is seen 438 
in humans. Our study design incorporates a sub-group analysis, which may increase the risk 439 
of a type II error; to defend against this we have performed a main analysis (Control vs ANS 440 
Groups) to confirm overall effect. We then performed sub-group analyses only on relevant 441 
physiological changes that were statistically signif cant in the main analysis. Testing these 442 
findings in a clinical setting would require significantly larger numbers of subjects than used 443 
herein before a conclusive result could be obtained. 444 
 445 
It is unknown whether lambs in the Non-Responder Sub-Group could have developed a 446 
degree of functional lung maturation if they had been subjected to a subsequent course of 447 
ANS therapy - although it was not possible to assess thi  point given the study design used. 448 
However, considering that the variability of ANS efficacy between the Responder Sub-Group 449 
and the Non-Responder Sub-Group was not due to betameth sone distribution, clearance or 450 
protein binding ratio it is tempting to speculate that individual sensitivity, perhaps at the 451 





Research Implications 456 
These data suggess that in addition to delivering a ecessary dose of steroids, ANS treatment 457 
efficacy additionally depends on pregnancy or fetus-specific factors. Further studies focusing 458 
on genetics and fetal responsiveness to ANS at various gestational ages are necessary. At the 459 
same time, optimized ANS therapies to deliver a more efficient outcome with an absolute 460 
minimum risk of adverse side effects need to be studied. 461 
 462 
Conclusion  463 
Our data show that adequate materno-fetal steroid exposure is not the sole determinant of 464 
ANS treatment efficacy. Although these data are from a comparatively small animal study, 465 
they do highlight that the optimization of dosing regimens, with an additional focus on 466 
individual patient responsiveness, may serve as an important avenue by which the efficacy 467 
and safety of ANS therapy may be improved. 468 
 469 
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[Tables] 550 
Table 1. Summary of delivery data.  551 
 552 
  Control  ANS Responder Non-responder 
n 9 19 12 7 
Gestational Age 
(d)  
122.2±0.8 122.0±0.8 122.0±0.8 122.0±0.8 
Birth Weight 
(kg) 
2.9±0.4 2.6±0.4 2.7±0.4 2.6±0.4 
Sex (M/F) 4/5 11/7♱ 8/3♱ 3/4 
Cord pH 7.30±0.10 7.27±0.04 7.26±0.05 7.27±0.03 
Cord blood 
pCO2 (mmHg) 
59.3±9.6 58.1±5.7 57.5±6.7 59.2±4.5 
Lung Wt(g/kg) 35.3±2.4 33.9±5.1 32.9±3.9 35.9±7.2 
 ♱=Sex not recorded for one animal 
  553 
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[FIGURE LEGENDS] 554 
Figure 1. Blood gas measurements and physiological parameters 555 
Arterial blood gas measurements and physiological parameters at 30 minutes ventilation of 556 
preterm lamb. A, pH (Control vs ANS, mean difference 0.15 [95% CI: 0.03 to 0.26], 557 
Responder vs Non-Responder, mean difference -0.23 [95% CI: -0.33 to 0.12]) B, PaCO2 558 
(Control vs ANS, mean difference -38.0 [95% CI: -60.1 to -15.9], Responder vs 559 
Non-Responder, mean difference 50.9 [95% CI: 35.8 to 66.1]) C, PaO2 (Control vs ANS, 560 
mean difference 55.6 [95% CI: 14.2 to 97.0], Responder vs Non-Responder, mean difference 561 
-68.5 [95% CI: -131.5 to -5.5]) *significant differnce between groups. Error bars represent 562 
±1 standard deviation. CI: Confidential Interval 563 
 564 
Figure 2. Ventilation data  565 
Ventilation data at 30 minutes of ventilation. A. There was no difference in dynamic 566 
compliance between the Control Group and the ANS Group (Control vs ANS, mean 567 
difference 0.08 [95% CI: -0.02 to 0.19]). Sub-Group analysis was not done. B. Tidal volume 568 
showed significant differences in both primary and Sub-Group analysis. (Control vs ANS, 569 
mean difference 1.32 [95% CI: 0.48 to 2.17], Responder vs Non-Responder, mean difference 570 
-1.51 [95% CI: -2.36 to -0.67]) C. Ventilation efficacy index showed significant differences 571 
in both primary and Sub-Group analysis. (Control vs ANS, mean difference 0.011 [95% CI: 572 
0.005 to 0.016], Responder vs Non-Responder, mean difference -0.015 [95% CI: -0.021 to 573 
-0.010]) *significant difference between groups. Error bars represent ±1 standard deviation.   574 
Vt, tidal volume; VEI, Ventilation Efficiency index 575 
 576 
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Figure 3. Lung maturation analysis. 577 
A, Statistic lung gas volume measured at a maximal pressure of 40 cmH2O. It showed 578 
significant differences in both primary and Sub-Group analysis. (Control vs ANS, mean 579 
difference 3.32 [95% CI: 1.23 to 5.40], Responder vs Non-Responder, mean difference -3.60 580 
[95% CI: -6.00 to -1.21]) *significant difference between groups. Error bars represent ±1 581 
standard deviation. B, Pressure-volume relationship for air inflation and deflation of the lung 582 
at necropsy. The lower line from 0 cmH2O to 40 cmH2O of pressure in each loop is air 583 
inflation and the higher lines from 40 cmH2O to 0 cmH2O of pressure are air deflation. The 584 
volume in each pressure was higher or almost same in Responder compared to 585 
Non-Responder, which means static lung compliance was higher in Responder than 586 
Non-Responder. The ANS group was not shown.   587 
V40, volume at 40 cmH2O; PV, pressure volume  588 
 589 
Figure 4. Messenger RNA quantification in fold change relative to control animals. 590 
Relative expression of mRNA transcript for surfactant protein A, B and C (SP-A, SP-B and 591 
SP-C), aquaporin 1 and 5 (AQP-1 and AQP-5) and epith lial sodium channel subunits B 592 
(ENaC-B). While all mRNA transcripts apart from SP-B were significantly increased in ANS 593 
Group compared to Control Group, there was no difference in Sub-Group analysis. Box 594 
margins represent 25th and 75th percentiles; horizontal line represents median value.  595 
*significant difference between groups. Circles represent outlier values >1.5 times the 596 




Figure 5. Plasma betamethasone concentrations plotted against time. 600 
Total (unbound + bound) betamethasone concentrations and free (unbound) betamethasone 601 
concentrations in both maternal and fetal plasma from drug administration to delivery were 602 
measured. A, total betamethasone concentrations in maternal plasma; B, free betamethasone 603 
concentrations in maternal plasma; C, total betamethasone concentrations in fetal plasma; D, 604 
free betamethasone concentrations in fetal plasma. There are no significant differences in 605 
each measurement between responder and non-responder. Data points represent mean group 606 
values. Error bars represent 1 standard deviation.  607 





